Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. REGN
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
REGN
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

REGN Price Prediction Next Week

Based on the provided data and current market conditions, let's analyze REGN's price movement for the next trading week.

Technical Analysis

The stock is showing bearish momentum with RSI at 37.79, indicating a moderately oversold condition but not yet at extreme levels. The stock closed at $675.79 on January 24, 2025, with a significant decline of -2.71% during regular trading hours . The price is currently trading well below both its 20-day moving average ($704.66) and 200-day moving average ($954.24), suggesting strong downward pressure.

News Sentiment and Fundamental Catalysts

  1. Eylea Competition Impact: Amgen's biosimilar entry has been pressuring REGN's stock since September 2024. The combined Eylea HD and Eylea achieved $1.5B in Q4 2024 sales, with Eylea HD contributing $305M.

  2. Pipeline Development: Regeneron has 40 drugs in development representing potential market opportunities exceeding $220B by 2030. Key near-term catalysts include:

  • Itepekimab COPD Phase 3 data expected in H2 2025
  • Fianlimab melanoma Phase 3 data in H2 2025
  • Linvoseltamab BLA resubmission with anticipated launch in mid-2025
  1. Analyst Sentiment: RBC Capital maintains a Buy rating with a $1,059 price target, while the consensus target is $1,026.65, suggesting a 50.97% upside potential.

Price Prediction for Next Week

Based on technical indicators and news sentiment:

  • Support levels: $672.02 (Fibonacci S1), $658.22 (Fibonacci S2)
  • Resistance levels: $716.70 (Fibonacci R1), $730.51 (Fibonacci R2)

The stock is likely to trade between $665-$690 next week, with a bearish bias due to:

  • Continued pressure from Eylea competition
  • Overall weak technical indicators
  • No immediate positive catalysts until H2 2025

Trading Recommendation SELL with the following strategy:

  • Entry: Current price ($675.79)
  • Stop loss: Above $695
  • Target: $665 (near Fibonacci S1)

Risk factors to monitor:

  • Any unexpected positive pipeline developments
  • Changes in biosimilar competition dynamics
  • Broader market sentiment shifts

Based on the provided data and current market conditions, let's analyze REGN's price movement for the next trading week.

Technical Analysis

The stock is showing bearish momentum with RSI at 37.79, indicating a moderately oversold condition but not yet at extreme levels. The stock closed at $675.79 on January 24, 2025, with a significant decline of -2.71% during regular trading hours . The price is currently trading well below both its 20-day moving average ($704.66) and 200-day moving average ($954.24), suggesting strong downward pressure.

News Sentiment and Fundamental Catalysts

  1. Eylea Competition Impact: Amgen's biosimilar entry has been pressuring REGN's stock since September 2024. The combined Eylea HD and Eylea achieved $1.5B in Q4 2024 sales, with Eylea HD contributing $305M.

  2. Pipeline Development: Regeneron has 40 drugs in development representing potential market opportunities exceeding $220B by 2030. Key near-term catalysts include:

  • Itepekimab COPD Phase 3 data expected in H2 2025
  • Fianlimab melanoma Phase 3 data in H2 2025
  • Linvoseltamab BLA resubmission with anticipated launch in mid-2025
  1. Analyst Sentiment: RBC Capital maintains a Buy rating with a $1,059 price target, while the consensus target is $1,026.65, suggesting a 50.97% upside potential.

Price Prediction for Next Week

Based on technical indicators and news sentiment:

  • Support levels: $672.02 (Fibonacci S1), $658.22 (Fibonacci S2)
  • Resistance levels: $716.70 (Fibonacci R1), $730.51 (Fibonacci R2)

The stock is likely to trade between $665-$690 next week, with a bearish bias due to:

  • Continued pressure from Eylea competition
  • Overall weak technical indicators
  • No immediate positive catalysts until H2 2025

Trading Recommendation SELL with the following strategy:

  • Entry: Current price ($675.79)
  • Stop loss: Above $695
  • Target: $665 (near Fibonacci S1)

Risk factors to monitor:

  • Any unexpected positive pipeline developments
  • Changes in biosimilar competition dynamics
  • Broader market sentiment shifts

REGN Similar Chart Price Prediction

The price of REGN is predicted to go up 31.42%, based on the high correlation periods with DBVT. The similarity of these two price pattern on the periods is 94.78%.

stocks logo

REGN

stocks logo

DBVT

Up: 31.42%Similarity: 94.78%

REGN Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

REGN Price Forecast($)

Potential Return(%)

2025

712.500

-0.790

2026

850.000

18.360

2027

600.000

-16.110

2028

1,200.000

67.100

2029

1,200.000

67.540

2030

1,200.000

67.540

What is REGN stock price prediction 2025 ?

REGN stock is currently priced at $712.50. Analysts project a potential price of $1,053 by the end of 2025, reflecting a 50% upside due to strong growth drivers like Dupixent and Libtayo, despite challenges with Eylea's biosimilar competition. This optimism is supported by Regeneron's robust pipeline and expected positive developments in 2025.

What is REGN stock price prediction 2026 ?

REGN's stock price in 2026 is projected to reach approximately $850-$900, driven by growth in Dupixent sales and pipeline advancements, despite challenges from Eylea's patent expiration and biosimilar competition. Analysts remain optimistic about Dupixent's expansion into new indications, which could offset revenue declines from Eylea. However, regulatory uncertainties and competitive pressures may limit upside potential.

What is REGN stock price prediction 2027 ?

Predicting the price of REGN stock in 2027 is challenging, but it could reach around $600 based on projected growth in its pipeline and increasing demand for its innovative therapies. The company's strong financial performance and potential new drug approvals may drive this growth. Additionally, favorable market conditions and advancements in biotechnology could further support this price target.

What is REGN stock price prediction 2028 ?

REGN's stock price in 2028 is projected to reach approximately $1,200. This estimate is based on the company's strong pipeline, particularly Dupixent's growth potential, and its ability to offset Eylea's revenue decline with new product launches. Additionally, favorable market conditions and consistent earnings growth support this optimistic outlook.

What is REGN stock price prediction 2029 ?

Predicting REGN's 2029 price, I estimate it could reach $1,200 per share. This projection is based on strong growth in Dupixent revenues, expanding indications, and a robust pipeline, despite challenges from Eylea's patent expiration. Continued innovation and diversification in its portfolio will likely drive long-term valuation.

What is REGN stock price prediction 2030 ?

REGN's stock price by 2030 is projected to reach approximately $1,200, driven by strong growth in its Dupixent franchise and potential expansion in oncology with Libtayo. However, challenges like Eylea's patent expiration and competition from biosimilars may temper growth. The company's diversified pipeline and strategic focus on innovation support this optimistic long-term outlook.

REGN Revenue Forecast

REGN EPS Forecast

REGN FAQs

What is revenue forecast for next quarter？

The market consensus for 's revenue in the upcoming quarter is projected to be approximately $3.593B USD.

What is eps forecast for next quarter？

The market consensus for 's eps in the upcoming quarter is projected to be approximately $10.948 USD.

REGN VS S&P500

Eylea has become the leading franchise in wet AMD and other ophthalmology markets because of its similar efficacy and more convenient dosing regimen compared with Lucentis and Avastin.

Dupixent's solid launch in severe atopic dermatitis and asthma is extending to several other allergy-related indications and COPD.

Positive early data for several bispecific antibodies in blood cancer and solid tumors supports the potential of Regeneron's in-house oncology program.

Ask Intellectia about REGN

REGN Analyst's Forecast

Trung Huynh

UBS

Strong Buy → Hold

Price Target

$1,130 → $738

Upside

+6.46%

UBS downgraded Regeneron to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect between the market's shorter-term focus on Eylea revenues versus Regeneron's focus on building a long-term sustainable business. Eylea high dose adoptions are still limited at this stage, and with the backdrop of branded and biosimilar competition, UBS does not expect an inflection in the near-term., the analyst tells investors in a research note. The firm models a 14% decrease in Eylea franchise revenue in 2025, which is 4% below consensus. UBS believes the stock's current valuation justifies its base business and pipeline opportunities, and expects investors to opt for names with higher short-term growth and more value-inflecting readouts in 2025.
Srikripa Devarakonda

Truist Securities

Strong Buy

Price Target

$1,126 → $1,004

Upside

+36.86%

William Pickering

Bernstein

Buy

Price Target

$1,110 → $1,070

Upside

+46.52%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free